adalimumab (preferred products) — Highmark
Uveitis (UV)
Initial criteria
- age ≥ 2 years
- diagnosis of non-infectious intermediate, posterior or panuveitis
- prescribed by or in consultation with an ophthalmologist
- experienced therapeutic failure or intolerance to at least one immunosuppressant (for example, azathioprine, 6‑mercaptopurine) OR immunosuppressants are contraindicated
Reauthorization criteria
- member has demonstrated disease stability or a beneficial response to therapy